Novartis sBLA for CAR-T Therapy Kymriah Accepted by FDA – Nasdaq
Pharmaceutical Business Review |
Novartis sBLA for CAR–T Therapy Kymriah Accepted by FDA
Nasdaq A novel immunocellular therapy and one-time treatment, Kymriah uses patient's T cells to fight cancer. CAR-T is manufactured for individual patients using their own cells thereby making it different from typical small molecule or biologic therapies … Novartis gets US priority review for Kymriah for adults with lymphoma Novartis' Kymriah nabs speedy reviews in US, Europe for lymphoma treatment US FDA grants priority review status to Novartis' sBLA for Kymriah to treat adults with r/r DLBCL |
